Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
NEJM Evidence is Scopus-indexed (Q1, CiteScore 11.7), WoS ESCI. Published by Massachussetts Medical Society.
Checked against the index lists dated .
ISSN 2766-5526Verify ISSN ↗
Publisher: Massachussetts Medical Society
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (miscellaneous) | 36 / 466 | 92nd | Q1 |
| Pharmacology | 29 / 328 | 91st | Q1 |
| Drug Discovery | 16 / 161 | 90th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present, best quartile Q1, CiteScore 11.7.
NEJM Evidence is Q1 in Medicine (miscellaneous) (rank 36 of 466), Q1 in Pharmacology (rank 29 of 328) and Q1 in Drug Discovery (rank 16 of 161), by CiteScore 2025.
NEJM Evidence is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 11.7, which places it in quartile Q1 at the 92nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 3.979, quartile Q1, with an H-index of 19.
NEJM Evidence is published by Massachussetts Medical Society. Its ISSN is 2766-5526.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
NEJM Evidence has an h-index of 56 and a 2-year mean of 6.39 citations per paper (OpenAlex). Its Scopus CiteScore is 11.7, quartile Q1. On 2-year citations it ranks #32 of 451 Scopus journals in Medicine (miscellaneous).
NEJM Evidence published 146 papers in 2025; its busiest recent year was 2022 with 151. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2026), authors are most often from United States (55.6%), Canada (7.4%) and China (4.8%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.